Primary Sclerosing Cholangitis Market is Anticipated to Witness Moderate Growth Owing to Increasing
February 19, 2024 ⚊ 1 Min read ⚊ Views 42 ⚊ BLOG
The primary sclerosing cholangitis market comprises drugs and treatments to manage the symptoms of primary sclerosing cholangitis, a rare disorder that causes inflammation and scarring in the bile ducts of the liver. Primary sclerosing cholangitis (PSC) is a rare long-term disease that causes narrowing and scarring of the bile ducts inside and outside the liver. Patients with PSC experience itching, jaundice, abdominal pain, fatigue, weight loss, and fever as the disease progresses. The increasing research funding for orphan and rare disease drug development coupled with innovations in drug therapies and drug delivery mechanisms are driving the growth of the primary sclerosing cholangitis market. However, limited disease awareness and lack of treatment options remain key challenges.
